IMRX — Immuneering Corp

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1790340 ·
Last close
$3.46
Market Cap
$224.08M
52W High
$8.48
52W Low
$3.32
ADV30
812,585
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -25,787,560 -24,192,583 182,561,047 58,226,805 13,880,350
Jun 2026 0 — -18,999,964 -17,270,427 202,055,327 41,324,682 11,320,301
Mar 2026 0 — -15,334,539 -13,460,895 214,809,790 47,321,566 8,291,619
Dec 2025 0 — -13,751,943 -11,580,010 231,985,010 128,645,025 13,501,042

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-56,752,670
Investing CF
$-141,318,060
Financing CF
$213,039,914
CapEx
$-238,462
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.04
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-311,051,406
Inventory
—
Receivables
—
ST Investments
$108,575,637
EBIT TTM
$-63,466,746
Pretax Income TTM
$-57,274,086
Interest Exp TTM
—
Analysts
6

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -59,375,728 -56,024,898 231,985,010 13,501,042 218,483,968 -45,344,595
Dec 2024 0 -64,071,655 -61,036,608 52,714,413 11,328,187 41,386,226 -54,999,571
Dec 2023 0 -58,413,285 -53,471,622 102,584,538 12,008,355 90,576,183 -48,968,634
Dec 2022 316,952 -51,745,339 -50,513,568 122,367,283 12,517,028 109,850,255 -44,101,265
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$4,720,061
NetIncome TTM
$-57,276,207
OpCashFlow TTM
—
Assets (Latest)
$202,055,327
Forward EPS
$-1.26

Max Pain — expiry 2027-01-15

max pain strike: $5.00 · spot: $3.50 · call oi: 899 · put oi: 605
Expected Move to 2027-01-15: ±$1.18 (33.57%) — implied range $2.33 – $4.67 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KROS Keros Therapeutics, Inc. $221.95M $11.31 —
ARCT Arcturus Therapeutics Holdings Inc. $229.72M $7.97 —
VNDA Vanda Pharmaceuticals Inc. $230.39M $3.81 —
PRLD Prelude Therapeutics Inc $216.05M $3.32 —
FTH Faeth Therapeutics, Inc. $233.63M $9.04 —

News headlines (Yahoo Finance, 1h cache)

Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
2026-11-18 12:30 · Yahoo
Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
2026-11-18 12:30 · Yahoo
Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties
2026-11-13 14:36 · Yahoo
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients
2026-11-12 12:30 · Yahoo
Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer
2026-11-12 12:30 · Yahoo
Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
2026-11-09 12:30 · Yahoo
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
2026-11-06 14:00 · Yahoo
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-04 21:05 · Yahoo
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
2026-11-04 12:30 · Yahoo
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-10-29 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.